What happened Juno stock?

What happened Juno stock?

Celgene will acquire all the outstanding shares of common stock of Juno through a tender offer for $87 per share in cash, or an aggregate of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene.

Is Juno publicly traded?

What is Juno Therapeutics’ stock symbol? Juno Therapeutics trades on the NASDAQ under the ticker symbol “JUNO.”

What happened to Juno Therapeutics?

A few months later, in January 2018, Celgene acquired Juno in a $9 billion deal. The New Jersey-based biotech company continues to operate Juno’s Seattle R&D space and its manufacturing facility in nearby Bothell, Wash. Giovanni Caforio, Bristol-Myers Squibb CEO.

What is the price of Celgene stock?

Key Turning Points

Who owns Juno Pharmaceuticals?

Bristol Myers Squibb
Juno Therapeutics/Parent organizations

Who bought Juno?

Gett made a significant move to consolidate its position in the U.S. — specifically the key New York market where it operated — when it acquired Juno, a smaller rival in the New York market, for about $250 million in 2017.

Is Fred Hutch a publicly traded company?

The Texas company raised $140 million when it listed its stock on the Nasdaq under the ticker “BLCM.” Fred Hutch remains a significant investor in the company, holding 4.6 percent of Juno’s shares.

Is Celgene still trading?

Celgene common stock ceased trading as of the close of trading today. On November 21, 2019, newly issued Bristol-Myers Squibb shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol “BMYRT.”

What is CELG RT?

CELG. RT | Bristol Myers Squibb Co. Rt Stock Overview (U.S.: NYSE) | Barron’s.

Is Juno owned by BMS?

On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene….Juno Therapeutics.